Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Foye

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|November 3, 2009
Cancer gene profiling in prostate cancerAdam Foye, Phillip G Febbo
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 12, 2005
Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitroZhengdong Wang, Adam Foye, Yusuo Chang, et al.
Prostate Cancer and Prostatic Diseases|April 15, 2020
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancerRahul Aggarwal, Gustavo Rubio Romero, Verena Friedl, et al.
Cancer Research|September 24, 2009
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagyBala S Balakumaran, Alessandro Porrello, David S Hsu, et al.
Radiology|August 9, 2013
Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic successCharles E Spritzer, P Diana Afonso, Emily N Vinson, et al.
Journal of Vascular and Interventional Radiology : JVIR|May 28, 2017
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor YieldMichael G Holmes, Erik Foss, Gabby Joseph, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
Nature Cell Biology|June 13, 2024
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progressionMeng Zhang, Martin Sjöström, Xiekui Cui, et al.
Cancer Research|July 11, 2024
An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor ProgressionRaunak Shrestha, Lisa N Chesner, Meng Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate CancerRahul R Aggarwal, Jacqueline Vuky, David VanderWeele, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|November 3, 2009
Cancer gene profiling in prostate cancerAdam Foye, Phillip G Febbo
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 12, 2005
Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitroZhengdong Wang, Adam Foye, Yusuo Chang, et al.
Prostate Cancer and Prostatic Diseases|April 15, 2020
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancerRahul Aggarwal, Gustavo Rubio Romero, Verena Friedl, et al.
Cancer Research|September 24, 2009
MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagyBala S Balakumaran, Alessandro Porrello, David S Hsu, et al.
Radiology|August 9, 2013
Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic successCharles E Spritzer, P Diana Afonso, Emily N Vinson, et al.
Journal of Vascular and Interventional Radiology : JVIR|May 28, 2017
CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor YieldMichael G Holmes, Erik Foss, Gabby Joseph, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancerWilliam S Chen, Eric L Feng, Rahul Aggarwal, et al.
Nature Cell Biology|June 13, 2024
Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progressionMeng Zhang, Martin Sjöström, Xiekui Cui, et al.
Cancer Research|July 11, 2024
An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor ProgressionRaunak Shrestha, Lisa N Chesner, Meng Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2025
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate CancerRahul R Aggarwal, Jacqueline Vuky, David VanderWeele, et al.
Pageof 4